•     MacroCure is a privately held specialty pharmaceutical company focused on advanced wound therapy

•     Its lead product is CureXcell™

•     A Pivotal Phase III trial is set to begin mid-2010 in the US, Canada and Israel

•     MacroCure is already receiving revenue from marketing CureXcell™ in Israel for pressure, diabetic foot, venous and post-operative wounds

•     It has world-wide blockbuster potential as determined by a leading US based marketing firm

•     More than 4,500 patients have already been treated

•     MacroCure features Strong IP protection

Technology

•       CureXcell™  contains a cocktail of activated white blood  cells which create the “right” cytokine environment for healing

•       CureXcell™ is produced by process consistent with EU and US standards

•       Broad of spectrum activity including in infected wounds

•       Easy to use (1/mo injections)

•       Pharmacoeconomic analysis in Israel shows CureXcell™ results major  health care savings

Contact Details
Address: 9 Bareket St., P.O. Box 7988, Kiryat Matalon, Petach-Tikva  49517
Phone:  03-923-5556
Fax: 03-923-5558
Email:  Mitchell@Macrocure.com       
Internet Site: www.macrocure.com

Exhibition Representative
Name: Mitchell Shirvan
Mobile: 052-725-6667
E-mail: Mitchell@macrocure.com

Category: Pharmaceutical/Biopharmaceutical